ADC Therapeutics (NYSE:ADCT – Get Free Report) announced its earnings results on Monday. The company reported ($0.56) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.56), Yahoo Finance reports. The firm had revenue of $18.05 million during the quarter, compared to analyst estimates of $18.19 million. ADC Therapeutics had a negative return on equity of 1,313.37% and a negative net margin of 344.15%. During the same quarter in the prior year, the company earned ($0.74) EPS.
ADC Therapeutics Trading Up 8.5 %
Shares of ADCT stock opened at $4.83 on Wednesday. The stock has a fifty day simple moving average of $4.58 and a two-hundred day simple moving average of $2.87. ADC Therapeutics has a twelve month low of $0.36 and a twelve month high of $6.04. The stock has a market capitalization of $399.97 million, a price-to-earnings ratio of -1.65 and a beta of 1.69.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on ADCT shares. Guggenheim reaffirmed a “buy” rating on shares of ADC Therapeutics in a research report on Friday, April 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of ADC Therapeutics in a report on Thursday, March 14th. Finally, HC Wainwright dropped their price target on shares of ADC Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.
ADC Therapeutics Company Profile
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
See Also
- Five stocks we like better than ADC Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Celsius Stock’s Post-Earnings Morning Dip, Better than Coffee
- Options Trading – Understanding Strike Price
- Chegg Chokes on AI Attempt, CEO Talks it Up As He Passes Torch
- 3 Small Caps With Big Return Potential
- Does Logitech’s EPS Beat Signal the Rebound of Video Gaming?
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
